Vistin Pharma ASA (LTS:0RAM) Debt-to-Asset : 0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RAM Vistin Pharma ASA LTS:0RAM
75 GF Score
Price kr20.20
GF Value kr25.71
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Vistin Pharma ASA Debt-to-Asset?

Vistin Pharma ASA LTS:0RAM -0.49% 75 Debt-to-Asset is 0.00 as of Mar. 2026. GuruFocus rates LTS:0RAM with a GF Score™ of 75/100 and a GF Value™ of kr25.71 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Vistin Pharma ASA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was kr0.0 Mil. Vistin Pharma ASA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was kr0.0 Mil. Vistin Pharma ASA's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2026 was kr453.6 Mil. Vistin Pharma ASA's debt to asset for the quarter that ended in Mar. 2026 was 0.00.

Vistin Pharma ASA  (LTS:0RAM) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Vistin Pharma ASA Debt-to-Asset Related Terms

Vistin Pharma ASA Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Vistin Pharma ASA's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistin Pharma ASA Debt-to-Asset Chart

Vistin Pharma ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.12 0.01 0.00 0.00

Vistin Pharma ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.10 0.05 0.00 0.00

LTS:0RAM vs ZTS, UTHR, VTRS: Debt-to-Asset Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vistin Pharma ASA Debt-to-Asset vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Vistin Pharma ASA's Debt-to-Asset falls into.


LTS:0RAM
75GF Score
Vistin Pharma ASA LTS:0RAM
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vistin Pharma ASA Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Vistin Pharma ASA's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 0.619) / 439.432
=0.00

Vistin Pharma ASA's Debt-to-Asset for the quarter that ended in Mar. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 0) / 453.558
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.00 mean?
Vistin Pharma ASA (LTS:0RAM) has a Debt-to-Asset of 0.00 as of Mar. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Vistin Pharma ASA and its competitors.
Is Vistin Pharma ASA's Debt-to-Asset too high?
Vistin Pharma ASA's current Debt-to-Asset is 0.00. Overall, Vistin Pharma ASA has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Debt-to-Asset compare to ZTS and UTHR?
Vistin Pharma ASA's Debt-to-Asset of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Drug Manufacturers company?
A good Debt-to-Asset depends on the Drug Manufacturers industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Vistin Pharma ASA and its competitors. Vistin Pharma ASA's current Debt-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.71, compared to a current price of kr20.20 — trading 21.4% below its estimated fair value. The current Debt-to-Asset is 0.00. Vistin Pharma ASA's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current Debt-to-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?

Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued. The current stock price of kr20.20 is trading 21.4% below its estimated GF Value™ of kr25.71. GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.

Key valuation signals for LTS:0RAM:

  • Debt-to-Asset: 0.00
  • GF Value™: kr25.71 vs. price of kr20.20 (21.4% below fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vistin Pharma ASA Business Description

Address Ostensjoveien 27, P.O. Box 6735 Etterstad, Oslo, NOR, 0661
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
75GF Score

Get the complete analysis for LTS:0RAM

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr20.20
Price
kr25.71
GF Value